Our findings also suggest, that HSC clones with acquired CSF3R mutations are not leukemic, but pre-leukemic clones with an increased susceptibility to secondary leukemogenic events (e.g., RUNX1 mutation, trisomy 21) and overt MDS or AML. The gene discussed is RUNX1; the disease is myelodysplastic syndrome.